Nivolumab Induced Autoimmune Like Gastritis: A case report |Biomedgrid
Journal: American Journal of Biomedical Science & Research (Vol.9, No. 1)Publication Date: 2020-05-26
Authors : A Mohamad Mubder; Laura Bach; Neha Varshney; Bhaskar Banerjee;
Page : 88-91
Keywords : Immune check point inhibitors; Anti-programmed cell death protein-1 antibodies; Nivolumab; Autoimmune like gastritis; Chemotherapy;
Abstract
Immune checkpoint inhibitors (ICPI) such as ipilimumab (anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody) and nivolumab (antiprogrammed cell death protein-1 (PD-1) antibodies) are novel chemotherapeutic agents used in multiple advanced metastatic malignancies. They are well known for their immune-related adverse events [1]. Although diarrhea and enterocolitis have been documented as gastrointestinal side effects of ICPI, gastritis has been rarely reported as a side effect of ICPI. Here, we present a case of a 65-years old female with advanced hepatocellular carcinoma who developed autoimmune like gastritis after treatment with Nivolumab [2].
Other Latest Articles
- The Need of Early Detection of Positive COVID-19 Patients in the Community by Viral Tests (e.g. RT-PCR Tests) and Antibody Tests (Serological Tests) to Stop the Spread |Biomedgrid
- Potential Role of ACE2 Inhibition in COVID-19 Severity |Biomedgrid
- Impact of SARS-CoV-2 On St-Elevation Myocardial Infarction (STEMI) |Biomedgrid
- Is Bevacizumab a Direct Cause of Osteonecrosis of the Jaw like Bisphosphonate? |Biomedgrid
- Evidence based study of Hypoglycemic Potential of Bitter Melon Peptide |Biomedgrid
Last modified: 2023-06-14 21:08:17